Amsterdam Molecular Falls as Much as 58% After EMA Decision

Amsterdam Molecular Therapeutics (AMT) Holding NV fell as much as 58 percent in Amsterdam trading after a European Medicines Agency panel said the company’s Glybera therapy for the genetic disorder disorder lipoprotein lipase deficiency wasn’t approvable at this time.

To contact the editor responsible for this story: Kristen Hallam at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.